PharmaNetics' heparin assay trial completed:
This article was originally published in Clinica
Executive Summary
PharmaNetics Inc has completed a Phase I field trial of its rapid in vitro assay for monitoring the anticoagulant effects of enoxaparin, Aventis Pharmaceutical's low molecular weight heparin product marketed in the US as Lovenox and elsewhere as Clexane. According to PharmaNetics, the results of the trial show a sufficient correlation with standard laboratory methods to justify proceeding with trials needed for FDA submission. PharmaNetics has optimised the assay's test card formulation and is now validating its manufacturing process.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.